Regulators say the nation's largest pharmacy benefit managers are partly to blame for the soaring cost of insulin in the U.S.

"Millions of Americans with diabetes need insulin to survive, yet for many of these vulnerable patients, their insulin drug costs have skyrocketed over the past decade thanks in part to powerful PBMs and their greed,